{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:00:33Z","timestamp":1789419633804,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is unclear whether <jats:italic>Saccharomyces boulardii<\/jats:italic> (<jats:italic>S. boulardii<\/jats:italic>) supplementation in standard triple therapy (STT) is effective in eradicating <jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori<\/jats:italic>) infection in children. We therefore conducted a meta-analysis of randomized controlled trials (RCTs) to assess the effect of <jats:italic>S. boulardii<\/jats:italic> supplementation on <jats:italic>H. pylori<\/jats:italic> eradication in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted electronic searches in PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure and Wanfang database from the beginning up to September 2023. A random-effects model was employed to calculate the pooled relative risk (RR) with 95% confidence intervals (CI) through a meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifteen RCTs (involving 2156 patients) were included in our meta-analysis. Results of the meta-analysis indicated that <jats:italic>S. boulardii<\/jats:italic> in combination with STT was more effective than STT alone (intention-to-treat analysis : 87.7% vs. 75.9%, RR\u2009=\u20091.14, 95% CI: 1.10\u20131.19, <jats:italic>P<\/jats:italic> &lt; 0.00001; per-protocol analysis : 88.5% vs. 76.3%, RR\u2009=\u20091.15, 95% CI: 1.10\u20131.19, <jats:italic>P<\/jats:italic> &lt; 0.00001). The <jats:italic>S. boulardii<\/jats:italic> supplementation group had a significantly lower incidence of total adverse events (n\u2009=\u20096 RCTs, 9.2% vs. 29.2%, RR\u2009=\u20090.32, 95% CI: 0.21\u20130.48, <jats:italic>P<\/jats:italic> &lt; 0.00001), diarrhea (n\u2009=\u200913 RCTs, 14.7% vs. 32.4%, RR\u2009=\u20090.46, 95% CI: 0.37\u20130.56, <jats:italic>P<\/jats:italic> &lt; 0.00001), and nausea (n\u2009=\u200911 RCTs, 12.7% vs. 21.3%, RR\u2009=\u20090.53, 95% CI: 0.40\u20130.72, <jats:italic>P<\/jats:italic> &lt; 0.0001) than STT group alone. Similar results were also observed in the incidence of vomiting, constipation, abdominal pain, abdominal distention, epigastric discomfort, poor appetite and stomatitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Current evidence indicated that <jats:italic>S. boulardii<\/jats:italic> supplementing with STT could improve the eradication rate of <jats:italic>H. pylori<\/jats:italic>, and concurrently decrease the incidence of total adverse events and gastrointestinal adverse events in children.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08896-4","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:02:16Z","timestamp":1702627336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Lian-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"8896_CR1","doi-asserted-by":"publisher","first-page":"1042070","DOI":"10.3389\/fcimb.2022.1042070","volume":"12","author":"B Liang","year":"2022","unstructured":"Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: from antibiotics to probiotics. Front Cell Infect Microbiol. 2022;12:1042070.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"8896_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","volume":"47","author":"M Zamani","year":"2018","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori Infection. Aliment Pharmacol Ther. 2018;47(7):868\u201376.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"8896_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori Infection. Nat Rev Dis Primers. 2023;9(1):19.","journal-title":"Nat Rev Dis Primers"},{"key":"8896_CR4","doi-asserted-by":"publisher","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al. Management of Helicobacter pylori Infection: the Maastricht VI\/Florence consensus report. Gut. 2022 Aug 8:gutjnl-2022-327745. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745. Epub ahead of print.","DOI":"10.1136\/gutjnl-2022-327745"},{"issue":"6","key":"8896_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/MPG.0000000000001594","volume":"64","author":"NL Jones","year":"2017","unstructured":"Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN\/NASPGHAN guidelines for the management of Helicobacter pylori in Children and adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991\u20131003.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"8896_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/ped.14388","volume":"62","author":"S Kato","year":"2020","unstructured":"Kato S, Shimizu T, Toyoda S, Gold BD, Ida S, Ishige T, et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori Infection in childhood. Pediatr Int. 2020;62(12):1315\u201331.","journal-title":"Pediatr Int"},{"issue":"7","key":"8896_CR7","first-page":"580","volume":"61","author":"Subspecialty Group of Gastroenterology, the Society of Pediatrics, Chinese Medical Association; National Children\u2032s Medical Center Digestive Specialist Alliance","year":"2023","unstructured":"Subspecialty Group of Gastroenterology, the Society of Pediatrics, Chinese Medical Association; National Children\u2032s Medical Center Digestive Specialist Alliance. Editorial Board, Chinese Journal of Pediatrics. Expert consensus on the diagnosis and management of Helicobacter pylori Infection in Chinese children (2022). Zhonghua Er Ke Za Zhi. 2023;61(7):580\u20137.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"4","key":"8896_CR8","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00253-018-09580-3","volume":"103","author":"N Qureshi","year":"2019","unstructured":"Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori Infection: a potential strategy against a serious pathogen? Appl Microbiol Biotechnol. 2019;103(4):1573\u201388.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"8896_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12876-021-01977-1","volume":"21","author":"M Keikha","year":"2021","unstructured":"Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric Infections. BMC Gastroenterol. 2021;21(1):388.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"8896_CR10","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00431-022-04523-7","volume":"181","author":"S Daelemans","year":"2022","unstructured":"Daelemans S, Deseck V, Levy EI, Vandenplas Y. Are pro- and\/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review. Eur J Pediatr. 2022;181(9):3225\u201334.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"8896_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","volume":"11","author":"C Hill","year":"2014","unstructured":"Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506\u201314.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"8896_CR12","doi-asserted-by":"publisher","first-page":"e12651","DOI":"10.1111\/hel.12651","volume":"24","author":"BG Zhou","year":"2019","unstructured":"Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651.","journal-title":"Helicobacter"},{"key":"8896_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"8896_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"8896_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"8896_CR16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","volume":"15","author":"R DerSimonian","year":"1996","unstructured":"DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237\u201348.","journal-title":"Stat Med"},{"issue":"7414","key":"8896_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"8896_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"8896_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith Gd, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"issue":"1","key":"8896_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1651-2227.2008.00977.x","volume":"98","author":"V Hurduc","year":"2009","unstructured":"Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori Infection in children. Acta Paediatr. 2009;98(1):127\u201331.","journal-title":"Acta Paediatr"},{"issue":"10","key":"8896_CR21","first-page":"928","volume":"30","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Li J. The effect of Saccharomyces boulardii on triple therapy for Helicobacter pylori Infection in children. J Clin Pediatr. 2012;30(10):928\u201331.","journal-title":"J Clin Pediatr"},{"issue":"1","key":"8896_CR22","first-page":"38","volume":"25","author":"H Zhang","year":"2013","unstructured":"Zhang H. Analysis of the therapeutic effect of combination therapy with Saccharomyces boulardii on Helicobacter pylori Infection in children. Chin Minkang Med. 2013;25(1):38\u201340.","journal-title":"Chin Minkang Med"},{"issue":"3","key":"8896_CR23","first-page":"230","volume":"16","author":"HM Zhao","year":"2014","unstructured":"Zhao HM, Ou-Yang HJ, Duan BP, Xu B, Chen ZR, Tang J, et al. Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori Infection in children. Zhong Guo Dang Dai Er Ke Za Zhi. 2014;16(3):230\u20133.","journal-title":"Zhong Guo Dang Dai Er Ke Za Zhi"},{"key":"8896_CR24","first-page":"71","volume":"13","author":"F Zhou","year":"2015","unstructured":"Zhou F, Li XQ. A study on the efficacy of combined triple therapy with Saccharomyces boulardii in eradicating Helicobacter pylori Infection in children. J China Modern Doctor. 2015;13:71\u20133.","journal-title":"J China Modern Doctor"},{"key":"8896_CR25","doi-asserted-by":"crossref","unstructured":"Bin Z, Ya-Zheng X, Zhao-Hui D, Bo C, Li-Rong J, Vandenplas Y. The Efficacy of Saccharomyces boulardii CNCM I-745 in Addition to Standard Helicobacter pylori Eradication Treatment in Children. Pediatric gastroenterology, hepatology & nutrition. 2015, 18(1):17-22.","DOI":"10.5223\/pghn.2015.18.1.17"},{"issue":"12","key":"8896_CR26","first-page":"865","volume":"23","author":"LZ Chen","year":"2015","unstructured":"Chen LZ. A study on drug treatment plans for Helicobacter pylori Infection in children. Chin J Integr Traditional Chin Western Med Digestion. 2015;23(12):865\u20137.","journal-title":"Chin J Integr Traditional Chin Western Med Digestion"},{"issue":"10","key":"8896_CR27","first-page":"1476","volume":"17","author":"LM Wang Ht, Kang","year":"2017","unstructured":"Wang Ht, Kang LM, Zhao Q. Observation of the efficacy of microecological adjuvant therapy in 107 children with Helicobacter pylori Infection. Chin J Med Clin Sci. 2017;17(10):1476\u20138.","journal-title":"Chin J Med Clin Sci"},{"issue":"5","key":"8896_CR28","first-page":"98","volume":"14","author":"M Xiang","year":"2017","unstructured":"Xiang M, Du M, Deng XZ, Shang LH. Clinical value of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori Infection in children. Practical Hosp Clin J. 2017;14(5):98\u2013101.","journal-title":"Practical Hosp Clin J"},{"issue":"11","key":"8896_CR29","first-page":"1287","volume":"44","author":"N Dong","year":"2018","unstructured":"Dong N, Xu W, Zhu DR, Sheng WS. The efficacy of triple therapy combined with probiotics in the treatment of Helicobacter pylori Infection in children. Jiangsu Med J. 2018;44(11):1287\u20139.","journal-title":"Jiangsu Med J"},{"issue":"02","key":"8896_CR30","first-page":"171","volume":"31","author":"J He","year":"2019","unstructured":"He J, Wang W, Gao CY. The treatment of Helicobacter pylori Infection in children with the combination of bladder\u2019s yeast powder and triple therapy. Chin J Microbiol. 2019;31(02):171\u20133.","journal-title":"Chin J Microbiol"},{"key":"8896_CR31","first-page":"1454","volume":"19","author":"J Zhu","year":"2019","unstructured":"Zhu J, Hu C, Lu M, Wang X, Liu Y, Luo Y, et al. Efficacy analysis of probiotic combined with standard treatment regimen for eradicating Helicobacter pylori in children. Chin J Practical Pediatr Clin. 2019;19:1454\u20137.","journal-title":"Chin J Practical Pediatr Clin"},{"issue":"20","key":"8896_CR32","first-page":"2861","volume":"25","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, Shao Z. Observation on the effect of Saccharomyces boulardii assisted eradication of Helicobacter pylori. Med Forum. 2021;25(20):2861\u20133.","journal-title":"Med Forum"},{"issue":"20","key":"8896_CR33","first-page":"3670","volume":"30","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wang Y, Li X, Zhang Y. The effect of adding Saccharomyces boulardii powder combined with triple therapy in the treatment of Helicobacter pylori Infection in children at different stages. Henan Med Res. 2021;30(20):3670\u20133.","journal-title":"Henan Med Res"},{"key":"8896_CR34","doi-asserted-by":"publisher","DOI":"10.27438\/d.cnki.gyadu.2022.000718","author":"QJ Liu","year":"2023","unstructured":"Liu QJ. A study on the efficacy of adding probiotics based on a first-line plan in the eradication of Helicobacter pylori. Yan\u2019an Univ. 2023. https:\/\/doi.org\/10.27438\/d.cnki.gyadu.2022.000718.","journal-title":"Yan\u2019an Univ"},{"issue":"6","key":"8896_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MCG.0b013e3182549092","volume":"46","author":"F Guarner","year":"2012","unstructured":"Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012;46(6):468\u201381.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"8896_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00431-008-0879-7","volume":"168","author":"Y Vandenplas","year":"2009","unstructured":"Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009;168(3):253\u201365.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"8896_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1365-2036.2007.03442.x","volume":"26","author":"D Czerucka","year":"2007","unstructured":"Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics-Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26(6):767\u201378.","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"8896_CR38","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.3748\/wjg.v16.i18.2202","volume":"16","author":"LV McFarland","year":"2010","unstructured":"McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202\u201322.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"8896_CR39","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apm.12237","volume":"122","author":"S Sakarya","year":"2014","unstructured":"Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for \u03b12,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122(10):941\u201350.","journal-title":"APMIS"},{"issue":"2","key":"8896_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF01536771","volume":"35","author":"JP Buts","year":"1990","unstructured":"Buts JP, Bernasconi P, Vaerman JP, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces Boulardii. Dig Dis Sci. 1990;35(2):251\u20136.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"8896_CR41","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/IAI.71.2.766-773.2003","volume":"71","author":"S Dahan","year":"2003","unstructured":"Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71(2):766\u201373.","journal-title":"Infect Immun"},{"issue":"2","key":"8896_CR42","doi-asserted-by":"publisher","first-page":"e12869","DOI":"10.1111\/hel.12869","volume":"27","author":"BG Zhou","year":"2022","unstructured":"Zhou BG, Yan XL, Wan LY, Zhang Q, Li B, Ai YW. Effect of enhanced patient instructions on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized controlled trials. Helicobacter. 2022;27(2):e12869.","journal-title":"Helicobacter"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08896-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T08:03:08Z","timestamp":1702627388000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08896-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8896"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08896-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"878"}}